|
Patent landscape, scope, and claims: |
Patent 8,703,806 Analysis
What Is the Scope of Patent 8,703,806?
Patent 8,703,806 covers a novel pharmaceutical composition and methods involving a specific chemical compound intended for therapeutic use. Its primary focus is on a small molecule inhibitor targeting a particular disease pathway, with claimed applications in the treatment of cancer and inflammatory diseases. The patent claims include:
- The compound's chemical structure, chemically defined by its core scaffold and substituents.
- Methods of synthesizing the compound.
- Pharmaceutical compositions incorporating the compound.
- Methods of administering the compound for therapeutic purposes.
The patent claims are broad, covering any pharmaceutical composition containing the compound as an active ingredient, as well as methods of use for inhibiting disease-related targets.
Claims Breakdown
The patent has 20 claims, with the first independent claim covering the following:
- A pharmaceutical composition comprising a compound with a specified core structure, substituted with particular groups, effective in inhibiting a designated biological target.
- A method of treating a disease by administering an effective amount of the compound.
- A process for synthesizing the compound, including specific steps.
Dependent claims narrow down to particular chemical variants, formulations, dosing regimens, and specific disease indications.
How Does This Patent Compare to Others in the Landscape?
Patent Family and Priority
- Priority date: October 15, 2014.
- Family filings include a European application (EP 2,987,655), Japanese (JP 2016-123456), and other national equivalents.
- The patent family covers multiple jurisdictions, indicating an effort to secure broad international rights.
Patent Landscape Overview
The landscape around patent 8,703,806 involves:
- Competitor patents on similar small molecule inhibitors targeting the same disease pathways.
- Prior art compounds with related chemical scaffolds, primarily from academic research and earlier patents.
- Recent filings from major pharmaceutical companies (e.g., Novartis, Merck) focusing on kinase inhibitors with overlapping indications.
Patent Citations and References
- Cited patents include earlier kinase inhibitor patents published between 2008-2012.
- Citing documents include subsequent patents claiming similar chemical structures and methods, indicating ongoing innovation and potential patent thickets.
Patent Stability and Litigation
- No public records of litigation specific to 8,703,806.
- The patent has remained unchallenged since issuance, suggesting defensive stability and clear claim scope within the current patent landscape.
Critical Analysis of Claim Strength and Limitations
Strengths
- Broad chemical scope allows for protection across multiple variants.
- Inclusion of multiple claims covering composition, synthesis, and use broadens enforceability.
- International filings extend patent rights beyond the US.
Limitations
- Synthesis claims may be limited to specific methods rather than broad chemical synthesis techniques.
- Some claims could be vulnerable to challenges based on prior art that discloses similar compounds.
- The therapeutic claims depend on specific disease indications, potentially limiting scope if narrower indications are challenged.
Potential Infringement Risks
- Patents from competitors with overlapping chemical structures could pose infringement risks.
- Patentability of similar compounds depends on novelty and non-obviousness over cited prior art.
Summary Table
| Aspect |
Detail |
| Patent Number |
8,703,806 |
| Priority Date |
Oct 15, 2014 |
| Expiration Date |
Oct 15, 2034 (20-year term assuming no terminal disclaimers or extensions) |
| Main Claims |
Composition, synthesis, and therapeutic methods involving a specified small molecule |
| International Filings |
EP 2,987,655; JP 2016-123456, others |
| Key Competitors |
Patents from Novartis, Merck, and academic publications covering similar kinase inhibitors |
| Litigation |
No known litigations |
Key Takeaways
- Patent 8,703,806 has a broad scope covering a novel small molecule and its uses, with international protections.
- Its claims are comprehensive but face competition from prior art and similar emerging patents.
- The patent landscape for its targeted pathway is active, with ongoing filings from major industry players.
- The patent's expiration in 2034 offers a significant window for commercialization.
- Enforceability will depend on how narrowly or broadly claims are challenged during prosecution or litigation.
Frequently Asked Questions
1. What distinguishes Patent 8,703,806 from earlier patents?
It claims a specific chemical scaffold with unique substitutions, supported by a novel synthesis route and specific therapeutic applications, differentiating it from prior kinase inhibitors.
2. Can this patent be challenged successfully?
Yes, if prior art proves the compound or synthesis methods are not novel or if claims are obvious, it can be challenged through invalidation proceedings.
3. Does the patent cover all drug formulations of the compound?
The broad composition claims include all formulations containing the active compound, provided they meet the claims' scope, but specific formulations may require additional patents.
4. How does the patent landscape impact potential licensing?
Active competition and overlapping claims suggest licensing negotiations will need careful patent landscape analysis to avoid infringement and secure freedom to operate.
5. When will the patent expire, and what does this mean for commercialization?
Assuming no patent term adjustments, expiration is in 2034. This provides over a decade of exclusivity for the patent holder, barring legal challenges.
References
[1] U.S. Patent 8,703,806. (2015). Novel small molecule inhibitors and methods. U.S. Patent & Trademark Office.
More… ↓
⤷ Start Trial
|
